Heart Failure: FDA policy could boost care for millions | Dapagliflozin for HFpEF | 'This pandemic is not over'

News You Need to Know Today

Thursday, September 23, 2021

Editor's Choice: Heart Failure

Updated FDA policy could improve treatment for up to 1.8 million HF patients

Expanded FDA labeling for sacubitril/valsartan could make a massive impact on patient care in the next three years.

Updated FDA policy could improve treatment for up to 1.8 million HF patients

Expanded FDA labeling for sacubitril/valsartan could make a massive impact on patient care in the next three years.

Dapagliflozin significantly improves HFpEF symptoms

One researcher described the findings, presented at the Heart Failure Society of America's Annual Scientific Meeting, as "great news for patients and clinicians."

USPSTF updates its stance on aspirin use to prevent CVD, sees no benefit for patients 60 or older.

Dapagliflozin significantly improves HFpEF symptoms

One researcher described the findings, presented at the Heart Failure Society of America's Annual Scientific Meeting, as "great news for patients and clinicians."

Cancer shortens lifespan of organ transplant patients, especially those receiving a new lung or heart

Nearly 6% of transplant recipients developed cancer within 10 years of the procedure, researchers reported.

Cancer shortens lifespan of organ transplant patients, especially those receiving a new lung or heart

Nearly 6% of transplant recipients developed cancer within 10 years of the procedure, researchers reported.

Specialists explore relationship between COVID-19 and heart failure, highlighting importance of vaccination

"The rise of the delta variant of COVID-19 is a reminder that this pandemic is not over," the president of the Heart Failure Society of America said in a statement.

Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues. #longcovid

Specialists explore relationship between COVID-19 and heart failure, highlighting importance of vaccination

"The rise of the delta variant of COVID-19 is a reminder that this pandemic is not over," the president of the Heart Failure Society of America said in a statement.

Risk of heart damage higher after COVID-19 than vaccination

The new analysis, published in the New England Journal of Medicine, included data from more than 2.1 million patients.

COVID-19 vaccines help reduce the serious coronavirus infections and hospitalizations. Multiple studies have shown that the risk from very rare vaccine side effects are far outweighed by the much greater risk of hospitalization and death due to COVID infections.

Risk of heart damage higher after COVID-19 than vaccination

The new analysis, published in the New England Journal of Medicine, included data from more than 2.1 million patients.

FDA-approved antiplatelet medication may be an effective heart failure treatment

Additional research is still needed, but researchers may have uncovered a new treatment for heart failure.

Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.

FDA-approved antiplatelet medication may be an effective heart failure treatment

Additional research is still needed, but researchers may have uncovered a new treatment for heart failure.

Making progress: Heart tissue developed in a laboratory shows promise

These findings, one specialist said, could provide a significant piece to "the puzzle of heart development."

Making progress: Heart tissue developed in a laboratory shows promise

These findings, one specialist said, could provide a significant piece to "the puzzle of heart development."

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us | Unsubscribe from all | Privacy Policy

© Innovate Healthcare, a TriMed Media brand

Editor's Choice: Heart Failure

Recent Newsletters